Literature DB >> 10965847

Casein kinase II phosphorylation of the human papillomavirus-18 E7 protein is critical for promoting S-phase entry.

W M Chien1, J N Parker, D C Schmidt-Grimminger, T R Broker, L T Chow.   

Abstract

The human papillomavirus type 18 E7 protein subverts the pRb/E2F pathway to promote S-phase reentry by postmitotic, differentiated primary human keratinocytes in support of viral DNA amplification. We prepared a panel of HPV-18 E7 mutations in pRb binding or in casein kinase II (CKII) phosphorylation. Our results showed that the ability of E7 binding to pRb correlated with the activation of DNA polymerase alpha or cyclin E to various extents in differentiated keratinocytes of organotypic cultures but was insufficient to induce the proliferating cell nuclear antigen. Proteins mutated in the CKII recognition sequence or in one or both serine substrates (S32 and S34) bound pRb in vitro, but only those with negative charges at these two residues induced proliferating cell nuclear antigen effectively. Nevertheless, unscheduled cellular DNA synthesis occurred very inefficiently relative to the wild-type E7, if at all. Thus, both pRb binding and CKII phosphorylation of E7 are critical for activating cellular genes essential for S-phase entry.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10965847

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  27 in total

Review 1.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

2.  Inhibition of human papillomavirus type 16 E7 phosphorylation by the S100 MRP-8/14 protein complex.

Authors:  Sharof Tugizov; Jennifer Berline; Rossana Herrera; Maria Elena Penaranda; Mayumi Nakagawa; Joel Palefsky
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Structure-based discovery of novel flavonol inhibitors of human protein kinase CK2.

Authors:  Andriy G Golub; Volodymyr G Bdzhola; Yaroslav V Kyshenia; Vladislav M Sapelkin; Andriy O Prykhod'ko; Olexander P Kukharenko; Olga V Ostrynska; Sergiy M Yarmoluk
Journal:  Mol Cell Biochem       Date:  2011-07-07       Impact factor: 3.396

Review 4.  The human papillomavirus E7 oncoprotein as a regulator of transcription.

Authors:  William K Songock; Seong-Man Kim; Jason M Bodily
Journal:  Virus Res       Date:  2016-11-08       Impact factor: 3.303

5.  Evaluation of ODE-Bn-PMEG, an acyclic nucleoside phosphonate prodrug, as an antiviral against productive HPV infection in 3D organotypic epithelial cultures.

Authors:  N Sanjib Banerjee; Hsu-Kun Wang; James R Beadle; Karl Y Hostetler; Louise T Chow
Journal:  Antiviral Res       Date:  2017-12-26       Impact factor: 5.970

6.  Conditionally activated E7 proteins of high-risk and low-risk human papillomaviruses induce S phase in postmitotic, differentiated human keratinocytes.

Authors:  N Sanjib Banerjee; Nicholas J Genovese; Francisco Noya; Wei-Ming Chien; Thomas R Broker; Louise T Chow
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

7.  Interactions with pocket proteins contribute to the role of human papillomavirus type 16 E7 in the papillomavirus life cycle.

Authors:  Asha S Collins; Tomomi Nakahara; Anh Do; Paul F Lambert
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

8.  The high-risk HPV16 E7 oncoprotein mediates interaction between the transcriptional coactivator CBP and the retinoblastoma protein pRb.

Authors:  Ariane L Jansma; Maria A Martinez-Yamout; Rong Liao; Peiqing Sun; H Jane Dyson; Peter E Wright
Journal:  J Mol Biol       Date:  2014-11-01       Impact factor: 5.469

9.  Nonconserved lysine residues attenuate the biological function of the low-risk human papillomavirus E7 protein.

Authors:  Nicholas J Genovese; Thomas R Broker; Louise T Chow
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

Review 10.  Human papillomavirus infections: warts or cancer?

Authors:  Louise T Chow; Thomas R Broker
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-07-01       Impact factor: 10.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.